About Biocon Biocon's Products & Services Research & Development Biocon's Technology Investors Media Careers CSR
  About Us
  Research & Development
  Branded Formulations
  Financial Results
  - Investor Call Invite
  - Investor Presentation
  - Chairman's Speech 2017
  - Disclosure to Stock Exchange
  - Annual Reports

 Annual Report 2018

Annual Report 2018

  - Enduring Edge: Biocon's Journey of Endurance
  - Biocon Profile
  - CMD Profile
  - Video Gallery


Biocon Malaysia


  Biocon Academy


  Facilities Virtual Tour

Biocon is Asia’s premier biopharmaceutical company that is driven by the vision to make a difference to global healthcare through improved access to high quality, life-saving biotherapeutics by making them affordable for patients across the world.

We have evolved from manufacturing pharmaceuticals like statins and immunosuppresants, to discovering, developing and producing biologics in chronic therapies such as diabetes, oncology and immunology for global markets. This has translated into a diversified and differentiated pipeline of fermentation-derived complex generics, biosimilars that include insulins and monoclonal antibodies, and novel biologics.

Biocon is among the few companies globally to have received approvals for its biosimilars from developed countries like the U.S., EU, Australia and Japan. Our credibility as a serious player in the biosimilars sector was first established with the Japanese approval for Insulin Glargine. The credibility was enhanced when Biocon, along with partner Mylan, became the first globally to get biosimilar Trastuzumab and Pegfilgrastim approved in the U.S. in 2017 and 2018, respectively. We were also among the first few to receive Insulin Glargine approval in Europe and Australia for Insulin Glargine, both in partnership with Mylan. We have also established our presence in key emerging markets through safe, effective and high quality biosimilars including recombinant human insulin.

A combination of specialized talent, state-of-the-art research and manufacturing infrastructure and a culture of deep science and regulatory compliance have differentiated us in the marketplace and given us a distinct competitive edge. It has also led to Biocon being recognized as a credible global biopharmaceuticals player.



Biocon Q2FY19 Performance Highlights by Kiran Mazumdar-Shaw, CMD, Biocon

Keynote Address delivered by Kiran Mazumdar-Shaw, CMD, Biocon at the GAP Summit 2018

Biocon: Engaged in Affordable
Innovation for Global Impact
Stock Update


Company Announcements


December 19, 2018 
 Biosimilar Trastuzumab Co-Developed by Biocon Receives Approval in the EU

December 17, 2018 
 Biocon's APIs Manufacturing Facility in Telangana Completes U.S. FDA Inspection with No 483 Observations

December 02, 2018 
 Biocon Foundation Dedicates Rejuvenated Hebbagodi Lake and Children's Park to the Community

November 30, 2018 
 Biosimilar Pegfilgrastim Co-Developed by Biocon Receives Approval in EU

  Media Coverage  

  Apr 27, 2018:   Biocon Q4 profit rises 2% to Rs130 crore

 Mar 27, 2018:   Mylan and Biocon Receive Approvals from the European Commission and TGA Australia for SemgleeTM, Biosimilar Insulin Glargine








Recommended sites Biocon on  
About Us

Investor Relations
Media Relations
Site Map
Contact Us
Our Growth Accelerators
Fact Sheet
Branded Formulations
Research Services
Active Discovery Program

Karnataka Vision Group on BT
Syngene International
Biocon Academy

    Linked In   
  Report adverse event/side effects and product complaints    
  * Disclaimer            © 2018, Biocon. All Rights Reserved